The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic Leukemia
The purpose of this study is to evaluate the level of a specific protein (PTEN) in the cancer cells of chronic myelomonocytic leukemia (CMML) patients. This protein might be involved in the transformation from normal blood cells to leukemia cells. The PTEN protein has not been investigated in CMML specifically but it has been discovered in closely related cancers. If this study demonstrates an abnormality in this protein, future testing will be designed to evaluate the genetic abnormality that resulted in lack of the normal presence of this protein. The goal is that the results of this study will help to develop new drugs and strategies to treat the future patients with CMML by understanding the abnormality of the disease at the cellular and molecular levels. The results of this study can also be utilized by future studies to develop individualized treatment to patients who have abnormal levels of this protein.
Chronic Myelomonocytic Leukemia
|Study Design:||Observational Model: Case Control
Time Perspective: Prospective
|Official Title:||The Expression of PTEN Protein and mRNA in Malignant Cells of Chronic Myelomonocytic Leukemia|
|Study Start Date:||November 2009|
|Estimated Primary Completion Date:||January 2017 (Final data collection date for primary outcome measure)|
Subjects diagnosed with CMML
Subjects ages 18 and older with a CMML diagnosis based on the WHO 2009 criteria, and who have signed an informed consent are eligible to participate in the study population of this clinical trial. A total of 12 patients will be consented.
The control group will consist of subjects ages 18 years or older who are healthy (i.e. no hematologic disorders) and have signed an informed consent. A total of 10 healthy control subjects will be consented.
Please refer to this study by its ClinicalTrials.gov identifier: NCT01010256
|United States, Arkansas|
|University of Arkansas for Medical Sciences||Recruiting|
|Little Rock, Arkansas, United States, 72205|
|Contact: Suzy Hall Hallsusanf@uams.edu|
|Principal Investigator: Peter Emanuel, MD|
|Principal Investigator:||Peter Emanuel, MD||University of Arkansas|